Cerella

VeraChem LLC was founded in 2000 to advance the state of the art in computer-aided drug discovery and molecular design by developing computational chemistry methods that are based on cutting-edge basic science but are also applicable in applied science research settings. Efficient high-performance software implementations of these methods coupled with comprehensive user support are a central company strategy for product development. Current VeraChem software capabilities include protein-ligand and host-guest binding affinity prediction, fast calculation of accurate partial atomic charges for drug-like compounds, computation of energies and forces with all the commonly used empirical force fields, automatic generation of alternate resonance forms of drug-like compounds, conformational search with the powerful Tork algorithm, and automatic detection of topological and 3D molecular symmetries. VeraChem’s software packages are constructed from a modular code base.

BIOiSIMTM is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illnesses or diseases. We offer a range of translational-based solutions, customized for your pre-clinical and clinical programs. These offerings are all centered around our proven and validated BIOiSIMTM platform for small molecules, large molecules, and viruses. Our models are built on data from thousands of compounds across 7 species, leading to robustness rarely seen in the industry. With a focus on human outcomes, the platform has at its core a translatability engine that transforms insights across species. The BIOiSIMTM platform can be used before the preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.